Acute lymphoblastic leukaemia

Simple item page
dc.contributor.authorInaba, H.
dc.contributor.authorGreaves, M.
dc.contributor.authorMullighan, C.G.
dc.date.issued2013
dc.description.abstractAcute lymphoblastic leukaemia occurs in both children and adults but its incidence peaks between 2 and 5 years of age. Causation is multifactorial and exogenous or endogenous exposures, genetic susceptibility, and chance have roles. Survival in paediatric acute lymphoblastic leukaemia has improved to roughly 90% in trials with risk stratification by biological features of leukaemic cells and response to treatment, treatment modification based on patients' pharmacodynamics and pharmacogenomics, and improved supportive care. However, innovative approaches are needed to further improve survival while reducing adverse effects. Prognosis remains poor in infants and adults. Genome-wide profiling of germline and leukaemic cell DNA has identified novel submicroscopic structural genetic changes and sequence mutations that contribute to leukaemogenesis, define new disease subtypes, affect responsiveness to treatment, and might provide novel prognostic markers and therapeutic targets for personalised medicine.
dc.description.statementofresponsibilityHiroto Inaba, Mel Greaves, Charles G Mullighan
dc.identifier.citationThe Lancet, 2013; 381(9881):1943-1955
dc.identifier.doi10.1016/S0140-6736(12)62187-4
dc.identifier.issn0140-6736
dc.identifier.issn1474-547X
dc.identifier.orcidMullighan, C.G. [0000-0002-1871-1850]
dc.identifier.urihttp://hdl.handle.net/2440/117014
dc.language.isoen
dc.publisherElsevier
dc.rights© 2013 Elsevier Ltd. All rights reserved.
dc.source.urihttps://doi.org/10.1016/s0140-6736(12)62187-4
dc.subjectCentral Nervous System Diseases
dc.titleAcute lymphoblastic leukaemia
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Genetics publications